Evidence map›Paper›PMID 35167779›Full record

Trial reportJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics2022

Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study.

David L Wirta, Yasuaki Kuwayama, Fenghe Lu, Hui Shao, Noriko Odani-Kawabata

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

David L WirtaEye Research Foundation, Newport Beach, California, USA.
Yasuaki KuwayamaFukushima Eye Clinic, Osaka, Japan.
Fenghe LuProduct Development Division (FHL, HS), Santen, Inc., Emeryville, California, USA.
Hui ShaoProduct Development Division (FHL, HS), Santen, Inc., Emeryville, California, USA.
Noriko Odani-KawabataProduct Development Division (FHL, HS), Santen, Inc., Emeryville, California, USA.
Santen (United States) · USSanten (Japan) · JPTokushima Breast Care Clinic · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Glaucoma, Open-AngleOcular HypertensionProstaglandins F, SyntheticAntiglaucoma AgentsAntihypertensive AgentsDouble-Blind MethodHumansInfantIntraocular PressureLatanoprostOphthalmic SolutionsTreatment OutcomeAntiglaucoma AgentsAntihypertensive AgentsLatanoprostOphthalmic SolutionsProstaglandins F, SyntheticFP and EP3 dual agonistglaucomaintraocular pressureocular hypertensionopen-angle glaucomasepetaprost

Identifiers

PMID35167779
PMCPMC9048176
OpenAlexW4213385330

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.